Program
Moxifloxacin
Also written as “Avelox (Moxifloxacin, BAY12-8039)”, “Moxifloxacin (Avelox, BAY12-8039)” and “moxifloxacin”.
Its studies are mostly in Cataract · Conjunctivitis, Bacterial · Otitis Media · Sinusitis · Community-Acquired Pneumonia, led by 14 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 200 open or running | phase 4since Jun 26, 2007 | Nov 21, 2006 | none ahead |
| Alcon | 140 open or running | phase 4since Apr 4, 2006 | Apr 4, 2006 | none ahead |
| Pfizer | 40 open or running | phase 1since Jul 10, 2007 | Jul 10, 2007 | none ahead |
| GlaxoSmithKline | 30 open or running | phase 1since Oct 8, 2009 | Oct 8, 2009 | none ahead |
| da-volterra | 20 open or running | phase 1since Jun 25, 2014 | Jun 25, 2014 | none ahead |
| Laboratorios Sophia S.A de C.V. | 21 open or running | phase 3since Jul 30, 2025 | Apr 9, 2024 | none ahead |
| richmond-pharmacology-limited | 20 open or running | phase 1since Jun 19, 2012 | Jun 19, 2012 | none ahead |
| Viatris | 20 open or running | phase 1since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| adapt-produtos-oftalmolo-gicos-ltda | 10 open or running | phase 3since Mar 22, 2011 | Mar 22, 2011 | none ahead |
| Dr. Reddy's Laboratories | 10 open or running | phase 1since Dec 18, 2014 | Dec 18, 2014 | none ahead |
| Intarcia Therapeutics | 10 open or running | phase 1since Jan 1, 2016 | Jan 1, 2016 | none ahead |
| jason-ahee-m-d | 11 open or running | phase 3since Aug 4, 2017 | Aug 4, 2017 | Oct 2030phase 3 · NCT03244072 |
| research-insight-llc | 10 open or running | phase 4since Dec 18, 2019 | Dec 18, 2019 | none ahead |
| richmond-research-institute | 10 open or running | phase 1since Nov 8, 2013 | Nov 8, 2013 | none ahead |
Also a collaborator on its studies: AbbVie, parexel, Bristol-Myers Squibb, topical-solutions-ltd and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 41 studies since Sep 7, 2005.
- May 22, 2013Phase 1 study in HealthyPfizer · NCT01862887 · 48 enrolled · United States
- Nov 8, 2013richmond-research-institute's first study: phase 1 study in Diabetes MellitusNew to richmond-research-instituterichmond-research-institute · NCT01984827 · 24 enrolled · United Kingdom
- Jun 25, 2014da-volterra's first study: phase 1 study in HealthyNew to da-volterrada-volterra · NCT02176005 · 44 enrolled · France
- Dec 18, 2014Dr. Reddy's Laboratories's first study: phase 1 study in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT02322619 · 26 enrolled
- Jan 1, 2016Intarcia Therapeutics's first study: phase 1 study in Healthy Adult Male and Female VolunteersNew to Intarcia TherapeuticsIntarcia Therapeutics · NCT02650479 · 82 enrolled · Netherlands
- Sep 19, 2016Phase 1 study in Healthy Subjectsda-volterra · NCT02917200 · 150 enrolled · France
- May 18, 2017Phase 1 study in Healthy VolunteersPfizer · NCT03162900 · 36 enrolled · Belgium
- Aug 4, 2017jason-ahee-m-d's first study: phase 3 study in EndophthalmitisNew to jason-ahee-m-djason-ahee-m-d · NCT03244072 · 60,000 planned · United States
- Dec 18, 2019research-insight-llc's first study: phase 4 study in CataractNew to research-insight-llcresearch-insight-llc · NCT04273282 · 31 enrolled · United States
- Jan 29, 2020Phase 1 study in Healthy SubjectsViatris · NCT04255277 · 97 enrolled · France
- Jul 28, 2022Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT05481528 · 51 enrolled · Germany
- Apr 18, 2023No phase study in Diabetes Mellitus, Type 2richmond-pharmacology-limited · NCT07014735 · 14 enrolled · United Kingdom
- Apr 9, 2024Laboratorios Sophia S.A de C.V.'s first study: phase 1 study in Conjunctivitis, BacterialNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT06363292 · 37 enrolled · Mexico
- Jul 30, 2025Phase 3 study in Cataract ExtractionLaboratorios Sophia S.A de C.V. · NCT07305987 · 134 planned · Mexico
Ahead
- Oct 2030Primary completion: phase 3 study in Endophthalmitisjason-ahee-m-d · NCT03244072
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor”ChEMBL 37, by rule
Studies
All 55 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07305987Cataract Extraction · Mexico | 3 | Recruiting | Laboratorios Sophia S.A de C.V. | Jun 30, 2026 | 134 |
| NCT06363292Conjunctivitis, Bacterial · Mexico | 1 | Completed | Laboratorios Sophia S.A de C.V. | May 28, 2024 | 37 |
| NCT07014735Diabetes Mellitus, Type 2 · United Kingdom | – | Terminated | richmond-pharmacology-limited | May 31, 2026 | 14 |
| NCT05481528Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Feb 7, 2023 | 51 |
| NCT04255277Healthy Subjects · France | 1 | Completed | Viatris | Sep 14, 2021 | 97 |
| NCT04273282Cataract · United States | 4 | Completed | research-insight-llc | Nov 24, 2020 | 31 |
| NCT03244072Endophthalmitis · United States | 3 | Not yet recruiting | jason-ahee-m-d | Oct 2030 | 60,000 |
| NCT03162900Healthy Volunteers · Belgium | 1 | Completed | Pfizer | Sep 23, 2017 | 36 |
| NCT02917200Healthy Subjects · France | 1 | Completed | da-volterra | Dec 2, 2016 | 150 |
| NCT02650479Healthy Adult Male and Female Volunteers · Netherlands | 1 | Completed | Intarcia Therapeutics | Apr 2016 | 82 |
| NCT02322619Healthy | 1 | Completed | Dr. Reddy's Laboratories | Dec 2012 | 26 |
| NCT02176005Healthy · France | 1 | Completed | da-volterra | Oct 2014 | 44 |
| NCT01984827Diabetes Mellitus · United Kingdom | 1 | Completed | richmond-research-institute | Dec 31, 2020 | 24 |
| NCT01862887Healthy · United States | 1 | Completed | Pfizer | Aug 2013 | 48 |
| NCT01859702Cataract | 4 | Completed | Alcon | Aug 2012 | 36 |
| NCT01775761TTR Cardiomyopathy · United States, Belgium, Singapore | 1 | Completed | Pfizer | Apr 2013 | 42 |
| NCT01642485Insulin Resistance · United Kingdom | 1 | Completed | richmond-pharmacology-limited | Sep 2011 | 32 |
| NCT01573910Conjunctivitis, Bacterial · China | 3 | Completed | Alcon | Apr 2014 | 985 |
| NCT01515826Cataract | 3 | Withdrawn | Alcon | Oct 2014 | 0 |
| NCT01449188Nausea · United States | 1 | Completed | GlaxoSmithKline | Dec 19, 2011 | 60 |
| NCT01406262Diabetes Mellitus, Type 2 | 1 | Completed | GlaxoSmithKline | Dec 29, 2011 | 94 |
| NCT01603030Eye Infections · Brazil | 3 | UNKNOWN | adapt-produtos-oftalmolo-gicos-ltda | Aug 2012 | 66 |
| NCT01238783Conjunctivitis, Bacterial | 2 | Withdrawn | Alcon | Dec 2011 | 0 |
| NCT01073891Healthy · Germany | 1 | Completed | Bayer | Nov 2010 | 24 |
| NCT01071902Otitis Media · United States | 3 | Terminated | Alcon | Oct 2011 | 400 |
| NCT01069900Intraabdominal Infections · United States, Argentina, Bulgaria and more | 3 | Completed | Bayer | Jan 21, 2015 | 458 |
| NCT01049022Infections · United States | 1 | Completed | Bayer | Dec 2012 | 31 |
| NCT01045902Pneumonia, Aspiration · Germany | 3 | Completed | Bayer | 139 | |
| NCT01014247QTc Evaluation · Australia, Germany, Singapore and more | 1 | Completed | Bayer | Jun 2010 | 56 |
| NCT00996021Healthy Subjects · United States | 1 | Completed | GlaxoSmithKline | Nov 2009 | 42 |
| NCT00840580Cataract · Korea, Republic of | 4 | Completed | Alcon | Sep 2009 | 79 |
| NCT00828971Communicable Diseases · Italy | 3 | Completed | Bayer | Sep 2009 | 16 |
| NCT00798577Conjunctivitis, Bacterial · United States | 4 | Completed | Alcon | Feb 2009 | 24 |
| NCT00769171Intraabdominal Infections · China, Hong Kong, Indonesia and more | 3 | Completed | Bayer | Dec 2006 | 364 |
| NCT00870103Cataract · United States | 4 | Completed | Alcon | Feb 2009 | 64 |
| NCT00750633Otitis Externa | 3 | Completed | Alcon | Jan 2009 | 990 |
| NCT00717561Pneumonia · Italy | 3 | Completed | Bayer | May 2009 | 60 |
| NCT00683865Pelvic Inflammatory Disease · Denmark, Finland, France and more | 3 | Completed | Bayer | Oct 2004 | 749 |
| NCT00668304Maxillary Sinusitis · United States, Argentina | 4 | Completed | Bayer | 192 | |
| NCT00665327Pneumonia · United States, Puerto Rico | 4 | Completed | Bayer | Apr 2004 | 401 |
| NCT00656747Bronchitis, Chronic · Andorra, Argentina, Australia and more | 4 | Completed | Bayer | Dec 2010 | 1,372 |
| NCT00579189Otitis Media | 3 | Completed | Alcon | Jan 2009 | 776 |
| NCT00579020Corneal Diseases · United States | 2 | Terminated | Alcon | Feb 2009 | 144 |
| NCT00578773Otitis Media | 2 | Completed | Alcon | Jan 2009 | 303 |
| NCT00578474Otitis Media | 3 | Completed | Alcon | Aug 2008 | 911 |
| NCT00499642Alzheimer Disease · France | 1 | Completed | Pfizer | ||
| NCT00493038Sinusitis · Italy | 4 | Terminated | Bayer | Jan 2008 | 293 |
| NCT00492726Infections · Argentina, Belgium, Bulgaria and more | 3 | Completed | Bayer | Feb 2009 | 804 |
| NCT00492024Sinusitis · United States | 3 | Completed | Bayer | Mar 2008 | 374 |
| NCT00473460Lung Diseases · United States, Andorra, Argentina and more | 3 | Completed | Bayer | Jan 2007 | 1,404 |
| NCT00453349Pelvic Inflammatory Disease · China, Indonesia, Korea, Republic of and more | 3 | Completed | Bayer | May 2008 | 460 |
| NCT00431678Pneumonia · Argentina, Belgium, Chile and more | 3 | Completed | Bayer | Jul 2005 | 738 |
| NCT00402727Abscess · Austria, Belgium, Bulgaria and more | 3 | Completed | Bayer | Jun 2008 | 813 |
| NCT00312338Conjunctivitis, Bacterial · United States | 4 | Completed | Alcon | Jun 2007 | 137 |
| NCT00158093Hypertension · United States | 1 | Completed | Viatris | 260 |
How it is read
Names in the registry
- “Moxifloxacin”, 32 entries
- “Avelox (Moxifloxacin, BAY12-8039)”, 11 entries
- “Moxifloxacin (Avelox, BAY12-8039)”, 9 entries
- “moxifloxacin”, 6 entries
- “Moxidex otic solution”, 5 entries
Conditions, from the studies’ own filings
- Cataract, 6 studies
- Conjunctivitis, Bacterial, 5 studies
- Otitis Media, 4 studies
- Sinusitis, 3 studies
- Community-Acquired Pneumonia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.